Format

Send to

Choose Destination
Enferm Infecc Microbiol Clin. 2015 Apr;33(4):257-67. doi: 10.1016/j.eimc.2015.03.001. Epub 2015 Mar 18.

[Meningococcal vaccines. Global epidemiological situation and strategies for prevention by vaccination].

[Article in Spanish]

Author information

1
Pediatría Clínica, Infectológica y Traslacional. Departamento de Pediatría, Hospital Clínico Universitario de Santiago, Unidad de Investigación en Vacunas, GENVIP, Instituto de Investigación Sanitaria de Santiago, Santiago de Compostela, La Coruña, España. Electronic address: irina667@hotmail.com.
2
Pediatría Clínica, Infectológica y Traslacional. Departamento de Pediatría, Hospital Clínico Universitario de Santiago, Unidad de Investigación en Vacunas, GENVIP, Instituto de Investigación Sanitaria de Santiago, Santiago de Compostela, La Coruña, España.

Abstract

N. meningitidis is a major cause of meningitis and septicemia and a major public health problem in many countries. The disease, that can be fulminant, has a high mortality and may cause serious sequelae, even in cases of apparently optimal medical treatment. Chemoprophylaxis may prevent secondary cases among those in close contact with the ill, but, since secondary cases represent only 1%-2% of all meningococcal disease, chemoprophylaxis has a small impact when fighting most of endemic and epidemic forms. Given that al least 5% -15% of children and young adults are carriers, the fight against meningococcal disease based on chemotherapeutic elimination of nasopharyngeal colonization is virtually impossible. Therefore, immunization is the only rational way to combat this disease.

KEYWORDS:

Antimeningococcal vaccines; Enfermedad meningocócica; Meningococcal disease; Neisseria meningitidis; Vacunas antimeningocócicas

PMID:
25795150
DOI:
10.1016/j.eimc.2015.03.001
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center